Cover Image

From anti-aging drugs to cancer therapy: is there a potential for sirtuin activators in gliomas?

See the article by Miller et al. pp. 53-62.Mutations in isocitrate dehydrogenase 1 (IDH1) and, to a lesser extent, IDH2 are hallmarks of lower-grade gliomas. IDH enzymes normally catalyze the decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), but the hotspot recurrent mutations in IDH conf...

Full description

Saved in:
Bibliographic Details
Main Authors: Opitz, Christiane (Author) , Turcan, S̨evin (Author)
Format: Article (Journal) Editorial
Language:English
Published: 2021
In: Neuro-Oncology
Year: 2021, Volume: 23, Issue: 1, Pages: 3-5
ISSN:1523-5866
DOI:10.1093/neuonc/noaa234
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/noaa234
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/23/1/3/5924499
Get full text
Author Notes:Christiane A. Opitz and Sevin Turcan

MARC

LEADER 00000caa a2200000 c 4500
001 1760690171
003 DE-627
005 20241128095444.0
007 cr uuu---uuuuu
008 210617s2021 xx |||||o 00| ||eng c
024 7 |a 10.1093/neuonc/noaa234  |2 doi 
035 |a (DE-627)1760690171 
035 |a (DE-599)KXP1760690171 
035 |a (OCoLC)1341416529 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Opitz, Christiane  |d 1979-  |e VerfasserIn  |0 (DE-588)132405121  |0 (DE-627)522675913  |0 (DE-576)299125041  |4 aut 
245 1 0 |a From anti-aging drugs to cancer therapy  |b is there a potential for sirtuin activators in gliomas?  |c Christiane A. Opitz and Sevin Turcan 
264 1 |c 2021 
300 |a 3 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Advance access date 16 October 2020 
500 |a Gesehen am 17.06.2021 
520 |a See the article by Miller et al. pp. 53-62.Mutations in isocitrate dehydrogenase 1 (IDH1) and, to a lesser extent, IDH2 are hallmarks of lower-grade gliomas. IDH enzymes normally catalyze the decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), but the hotspot recurrent mutations in IDH confer a neomorphic enzymatic activity that leads to overproduction of 2-hydroxyglutarate (2-HG) via NADPH-dependent reduction of α-KG.1 A distinctive outcome of 2-HG accumulation is the genome-wide DNA hypermethylation observed in IDH mutant tumors.2 In addition to its role in promoting epigenetic alterations, mutant IDH1 affects multiple metabolic pathways such as the citric acid cycle, glucose, glutamine, and lipid metabolism.3 To gain insights into these metabolic alterations and to determine whether they create metabolic vulnerabilities in IDH mutant tumors, further investigations are warranted. In this issue of Neuro-Oncology, Miller et al shed light on a metabolic Achilles’ heel in IDH mutant gliomas and demonstrate that sirtuin 1 (SIRT1) activation leads to augmented NAD+ depletion, reduced growth, and increased cytotoxicity when combined with nicotinamide phosphoribosyltransferase inhibitors (NAMPTi) in IDH mutant cells (Fig. 1).4 
700 1 |a Turcan, S̨evin  |e VerfasserIn  |0 (DE-588)1167189582  |0 (DE-627)103087414X  |0 (DE-576)511022093  |4 aut 
773 0 8 |i Enthalten in  |t Neuro-Oncology  |d Oxford : Oxford Univ. Press, 1999  |g 23(2021), 1 vom: Jan., Seite 3-5  |h Online-Ressource  |w (DE-627)357167341  |w (DE-600)2094060-9  |w (DE-576)318041839  |x 1523-5866  |7 nnas  |a From anti-aging drugs to cancer therapy is there a potential for sirtuin activators in gliomas? 
773 1 8 |g volume:23  |g year:2021  |g number:1  |g month:01  |g pages:3-5  |g extent:3  |a From anti-aging drugs to cancer therapy is there a potential for sirtuin activators in gliomas? 
856 4 0 |u https://doi.org/10.1093/neuonc/noaa234  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://academic.oup.com/neuro-oncology/article/23/1/3/5924499  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210617 
993 |a Editorial 
994 |a 2021 
998 |g 1167189582  |a Turcan, S̨evin  |m 1167189582:Turcan, S̨evin  |d 910000  |d 911100  |e 910000PT1167189582  |e 911100PT1167189582  |k 0/910000/  |k 1/910000/911100/  |p 2  |y j 
998 |g 132405121  |a Opitz, Christiane  |m 132405121:Opitz, Christiane  |d 910000  |d 911100  |e 910000PO132405121  |e 911100PO132405121  |k 0/910000/  |k 1/910000/911100/  |p 1  |x j 
999 |a KXP-PPN1760690171  |e 3938950919 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1760690171","title":[{"title":"From anti-aging drugs to cancer therapy","subtitle":"is there a potential for sirtuin activators in gliomas?","title_sort":"From anti-aging drugs to cancer therapy"}],"name":{"displayForm":["Christiane A. Opitz and Sevin Turcan"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"physDesc":[{"extent":"3 S."}],"note":["Advance access date 16 October 2020","Gesehen am 17.06.2021"],"person":[{"roleDisplay":"VerfasserIn","family":"Opitz","given":"Christiane","role":"aut","display":"Opitz, Christiane"},{"family":"Turcan","roleDisplay":"VerfasserIn","role":"aut","display":"Turcan, S̨evin","given":"S̨evin"}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"id":{"eki":["1760690171"],"doi":["10.1093/neuonc/noaa234"]},"relHost":[{"disp":"From anti-aging drugs to cancer therapy is there a potential for sirtuin activators in gliomas?Neuro-Oncology","title":[{"title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology","title_sort":"Neuro-Oncology"}],"recId":"357167341","pubHistory":["1.1999 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"part":{"extent":"3","volume":"23","issue":"1","year":"2021","pages":"3-5","text":"23(2021), 1 vom: Jan., Seite 3-5"},"note":["Gesehen am 21.07.23"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2094060-9"],"eki":["357167341"],"issn":["1523-5866"]},"origin":[{"dateIssuedKey":"1999","publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedDisp":"1999-","publisherPlace":"Oxford ; Durham, NC"}]}]} 
SRT |a OPITZCHRISFROMANTIAG2021 

Similar Items